Biosimilars are therapeutically similar copies of biologic drugs. The European Medicines Agency (EMA) defines biosimilars as drugs that claim to be “similar” to their reference biological medicinal products. The active drug substance of biosimilars is derived from a living organism by means of recombinant DNA or controlled gene expression methods. In the coming years, biosimilars will continue to act as a catalyst for the biopharmaceutical industry. The most significant reason for the increasing adoption of biosimilars is their cost benefits to patients as these products are available in the market at 10% to 30% lower prices compared to their parent products. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018.